Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Inclusion Criteria

• •Patients must have received first line standard chemotherapy and/or radiation therapy for neuroendocrine malignancy in the past and failed the therapy.
• •Patients must have evidence of residual multifocal active tumor.
• •All patients must sign an informed consent indicating the awareness of the investigational nature of the studies involved.
• •All patients must have a Karnofsky performance status of at least 60.
• •Patients must be greater than 18 years of age.
• •Patients must have measurable and/or followable disease based on either clinical or radiologic exam.
• •Sensitivity to Indium-111 pentetreotide or any of its components is an absolute contraindication to participation in this trial.
• •An absolute contraindication is pregnancy as evidenced by the clinical condition, a positive pregnancy test (Beta type Human chorionic gonadotropin (β-HCG) or pelvic ultrasound).
• •If patients have received prior radionuclide therapy of the same product, there must be documented response to that therapy and/or residual active stable disease.